Ana Martínez, PhD (Research Professor) VOLVER ARRIBA
e-mail address: amartinez iqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 585 4624/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Dr. Ana Martinez is Research Professor at Medicinal Chemistry Institute of Spanish National Council for Research (CSIC), having a background formation on Organic Chemistry. Her interest is focused on neurodegenerative disorders, leading numerous research projects on the medicinal chemistry and rational drug design of new drugs for Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis, spinal cord trauma and multiple sclerosis. Active areas of research involve GSK-3 inhibitors, BACE inhibitors, PDE 7 inhibitors, neurogenic drugs, CK 1 inhibitors among others. Since February 2002 till January 2008, she joined to NeuroPharma, currently named NOSCIRA, as R&D Director where she has provided strategic, leadership management and guidance in R&D activities, being two of her research compounds, named NP-12 and NP-61, in clinical trials as disease modifying agents for Alzheimer’s disease. She is author of more than a hundred and fifty scientific publications, more than twenty active patents in the field and editor of several books.
Santiago Conde, PhD (Staff Scientist) VOLVER ARRIBA
| e-mail address: scondeiqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 258 74 82/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Dr. Santiago Conde was originally formed as a synthetic organic chemist but since his doctoral thesis, dealing with analogs of 1,4-benzodiazepines, till now his current research activity in the neurodegenerative diseases area, he has always been devoted to the Medicinal Chemistry specialty. In this area, the organic chemistry is basically used as a tool to obtain molecules displaying the aimed biological activity and, besides the chemical background, a solid knowledge of the biochemical and/or pathological processes affected in the particular disease is also needed. Most of the Dr. Conde’s professional career has been developed in the Instituto de Química Médica (Medicinal Chemistry Institute) of the spanish CSIC. During the period 1982-89, he was working in a biotechnological company, Antibióticos S.A., as the head of the Organic Chemistry group in the Research Department of the company. In that time he was sent by the company to spent a 10 months stay in the Massachusetts Institute of Technology (M.I.T.) to study the new chemical methodology of enzymatic catalysis in organic solvents. Since 1996 he is working on the study of neurodegenerative diseases, in particular Alzheimer’s disease, aimed to find a potential treatment of this illness. He is author of more than forty scientific articles and fifteen patents and, since he come back to the Institute in 1989, he has developed six contracts with private companies, three of them as the main researcher
Carmen Gil, PhD (Staff Scientist) VOLVER ARRIBA
| e-mail address: cgiliqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 258 74 90/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Dr. Carmen Gil received her Ph.D. from Complutense University of Madrid in 2001 under the supervision of Dr. A. Martinez. After a postdoctoral appointment at Bonn University (Prof. Dr. Stefan Bräse), she joined the Medicinal Chemistry Institute in 2004 (first, as Associate Researcher and since 2007 as Staff Scientist) holding the responsibility of the design and synthesis of biologically active organic molecules in the neurodegenerative field.
Concepción Pérez, PhD (Research Specialist) VOLVER ARRIBA
| e-mail address: conchiiqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 258 75 78/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Dr. Concepción Pérez Martín is Research Specialist at Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). She obtained her doctorate from "Universidad Complutense" of Madrid (Spain) in 1995, investigating the differentiation of U937 promonocytic cells by antitumor DNA topoisomerase II inhibitors. At the present time her interest is focused on "in vitro" and "in vivo" evaluation of new drug with potential activity against neurodegenerative disorder, such as GSK-3 inhibitors, PDE 7 inhibitors, and neurogenic drugs.
Daniel Pérez, PhD (Research Associate) VOLVER ARRIBA
| e-mail address: dpereziqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 2587413/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Dr. Daniel I. Perez received his PhD degree from the Autonoma University of Madrid in November 2005. From 2003 to 2007 he worked as a researcher for the biopharmaceutical company NOSCIRA. During these years in industry, he has mainly been involved in different projects in the medicinal chemistry field. In 2007 he returned to academia with a postdoctoral position at Delft University of Technology (The Netherlands) in Prof. Sheldon´s group where he worked in the biocatalysis field. He joined the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC) in February 2009 as a postdoctoral researcher. Currently his research interests include the synthesis of different protein kinase inhibitors (e.g. GSK-3, CK1) and the use of different computational methods to find new lead compounds for the treatment of neurodegenerative diseases.
Valle Palomo (PhD student) VOLVER ARRIBA
| e-mail address: vpalomoiqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 2587413/ +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Valle Palomo finished her Chemistry studies in the Autonoma University of Madrid in June 2008. She joined the group in October 2008 and she is working on her PhD on the synthesis of protein kinase inhibitors GSK-3, as well as neurogenic drugs in the field of neurodegenerative diseases.
Miriam Redondo (PhD student) VOLVER ARRIBA
| e-mail address: miriamrsiqm.csic.es Office address: Medicinal Chemistry Institute-CSIC Juan de la Cierva 3 28006 Madrid (Spain) Phone: +34 91 258 74 23 / +34 91 562 29 00 Fax: +34 91 564 48 53 |
 |
Miriam Redondo finished her Pharmacy studies in the Alcalá de Henares University of Madrid in 2007. She joined the group in February 2008 and she is working on her PhD on the synthesis of phosphodiesterase 7 (PDE7) inhibitors, as well as neurogenic drugs in the field of neurodegenerative diseases.
